Improving Preschool Outcomes by Addressing Maternal Depression in Head Start

April 18, 2024 updated by: Brown University
Within a research network of Head Start centers in Massachusetts, an efficacy trial of a stepped-care intervention (SCI) to address maternal depression, using intervention components that both prevent depression and help those in major depressive episode (MDE) engage with care, will be conducted. Both the prevention and engagement components of the model have strong, supportive randomized trial evidence for both their efficacy and safety; but they have yet to be synthesized and tested within a coordinated intervention, applicable to a broad population base. Stepped-care interventions are commonly used in mental health service projects, in which the intensity or type of service is calibrated to the severity of illness.

Study Overview

Detailed Description

This research study is a community-based efficacy trial (n=388) of a stepped-care model intervention to strengthen the capacity of Head Start to address parental depression and related adversities. Head Start mothers with symptoms of depressed mood or anhedonia, and their Head Start children, are enrolled across 12 Head Start centers.

The research study aims to improve developmental outcomes for Head Start children by delivering stepped care intervention that incorporates depression prevention and linkage to formal mental health care to mothers. Mothers with low baseline depressive symptoms are offered a problem-solving intervention while mothers with greater symptoms are offered engagement sessions to link them to formal mental health services. At each problem-solving session participant's symptoms are assessed and if the symptoms meet pre-specified 'step-up' criteria, they are converted to Engagement sessions.

Over 12 months, the intervention's effect will be assessed on a series of outcome measures for mothers; mechanisms by which maternal depression is theorized to impact young children; and child outcomes.

Study Type

Interventional

Enrollment (Estimated)

388

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02119
        • Recruiting
        • Boston Medical Center
        • Contact:
          • Amy Yule, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Mother of a 0 to 5-year-old Head Start child, whose Head Start services will continue for at least 12 months following randomization
  • Mother endorses depressed mood or anhedonia on PHQ-9 (Patient Health Questionnaire-9)
  • Mother speaks English or Spanish
  • Mother is Medicaid beneficiary

Exclusion Criteria:

  • Mother with suicidal ideation
  • Mother with cognitive limitation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stepped-care intervention (SCI) group
In the SCI group, mothers with low baseline depressive symptoms are offered the problem-solving education (PSE) prevention intervention, and mothers with greater depressive symptoms are offered Engagement Sessions.
PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
Active Comparator: Usual care control group
Families in the control group will receive usual Head Start services.
Normal services provided children and their mothers in Head Start

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in incident rates of moderate to severe maternal depressive symptoms based on the QIDS
Time Frame: Baseline, 2, 4, 6, 8, 10, 12 months follow-up
The Quick Inventory of Depressive Symptoms (QIDS) will be used to assess the incidence of moderate to severe depressive symptom episodes, as defined by a QIDS score ≥ 11. The QIDS is a 16 item self-administered instrument with potential responses for each item of 0 to 3. Higher scores are associated with greater depressive symptoms.
Baseline, 2, 4, 6, 8, 10, 12 months follow-up
Change in the mean maternal depressive symptoms based on the QIDS
Time Frame: Baseline, 2, 4, 6, 8, 10, 12 months follow-up
The Quick Inventory of Depressive Symptoms will be used to assess depressive symptoms. The QIDS is a 16 item self-administered instrument with potential responses for each item of 0 to 3. Higher scores are associated with greater depressive symptoms. The mean QIDS scores will be calculated for the baseline and each follow up period.
Baseline, 2, 4, 6, 8, 10, 12 months follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of participants engaged with care based on 1 or more psycho/pharmacotherapy visits or psychiatric medication prescription
Time Frame: Baseline, 2, 4, 6, 8, 10, 12 months follow-up
The investigators have adapted the services section of the Collaborative Psychiatric Epidemiology Surveys, operationalized into engagement with care. This will be defined as ≥ 1 visit for psychotherapy or pharmacotherapy with a behavioral health specialist (social worker, psychologist, psychiatrist, psychiatric nurse); or a prescription for psychiatric medication from any medical practitioner.
Baseline, 2, 4, 6, 8, 10, 12 months follow-up
Rate of participants retained in care based on 4 or more psycho/pharmacotherapy visits or psychiatric medication prescription
Time Frame: 2, 4, 6, 8, 10, 12 months
The investigators have adapted the services section of the Collaborative Psychiatric Epidemiology Surveys, operationalized into retention in care. This will be defined as ≥ 4 visit for psychotherapy or pharmacotherapy with a behavioral health specialist (social worker, psychologist, psychiatrist, psychiatric nurse); or a prescription for psychiatric medication from any medical practitioner.
2, 4, 6, 8, 10, 12 months
Rate of participants who received evidence-based care defined by psychotherapy or antidepressant medication prescription
Time Frame: 2, 4, 6, 8, 10, 12 months
The investigators have adapted the services section of the Collaborative Psychiatric Epidemiology Surveys, operationalized into evidence-based care reflecting either psychotherapy or antidepressant medication.
2, 4, 6, 8, 10, 12 months
Rate of participants who received primary-care based services
Time Frame: 2, 4, 6, 8, 10, 12 months
The investigators have adapted the services section of the Collaborative Psychiatric Epidemiology Surveys, operationalized into primary care-based services.
2, 4, 6, 8, 10, 12 months
Burden of illness for depression
Time Frame: baseline; 6, 12 months
The Individual Burden of Illness Index for Depression (IBI-D) is a valid and reliable quality of life (QoL) scale, calculated as a composite of the QIDS, the QoL Enjoyment and Satisfaction Questionnaire, and the Work and Social Adjustment Scale
baseline; 6, 12 months
Child absenteeism from Head Start
Time Frame: baseline; 6, 12 months
Head Start centers will furnish us with monthly absentee rates for all families that provide explicit permission. These will be analyzed as count data against day of eligible attendance.
baseline; 6, 12 months
Caregiver-Teacher Report Form
Time Frame: baseline; 6, 12 months
This valid and reliable scale will be filled out by Head Start teachers. It measures emotional reactivity, anxiety/depression, somatic complaints, emotional withdrawal, attention problems, and aggressive behavior.
baseline; 6, 12 months
Social Skills Improvement System - Rating Scales
Time Frame: baseline; 6, 12 months
This valid and reliable scale will be filled out by Head Start teachers. It assesses social skills and problem behaviors for children at risk of interpersonal difficulties.
baseline; 6, 12 months
Bracken School Readiness Assessment
Time Frame: baseline; 6, 12 months
This scale assesses 85 foundational concepts, including colors, letters, numbers, size/ comparison, and shapes. Assess effect of intervention on child cognitive functioning and school readiness.
baseline; 6, 12 months
Perceived Stress
Time Frame: baseline, 4, 8, 12 months
Assess with The Perceived Stress Scale, domains of which include unpredictability, lack of control, burden overload, and stressful circumstances.
baseline, 4, 8, 12 months
Behavioral Activation for Depression
Time Frame: baseline, 4, 8, 12 months
Assess with The Behavioral Activation for Depression Scale (BADS) includes four affective and functional dimensions: activation, avoidance/rumination, work/school impairment, and social impairment.
baseline, 4, 8, 12 months
Coping Strategies
Time Frame: baseline, 4, 8, 12 months
Assess with The Brief COPE (Coping Orientation to Problems) which measures 14 different adaptive and problematic coping styles. Will also use problem-focused and avoidant subscales.
baseline, 4, 8, 12 months
Parent-Child Interaction
Time Frame: baseline, 6, 12 months
Assess with The Dyadic Parent-Child Interaction Coding System (4th Edition).
baseline, 6, 12 months
Family Conflict
Time Frame: Baseline, 6, 12 months
Assess with The 80-item Conflicts and Problem-Solving Scale. Likert scales rate aspects of family conflict known to affect children: 1) number of major and minor conflicts in the past year; 2) family disagreement in 21 areas; 3) frequency of 13 conflict resolution strategies; 4) frequency of 44 conflict tactics.
Baseline, 6, 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michael Silverstein, MD, Brown University
  • Principal Investigator: Amy Yule, MD, Boston Medical Center
  • Principal Investigator: Emily Feinberg, ScD CPNP, Brown University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 16, 2023

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

April 1, 2028

Study Registration Dates

First Submitted

September 13, 2019

First Submitted That Met QC Criteria

September 14, 2019

First Posted (Actual)

September 17, 2019

Study Record Updates

Last Update Posted (Actual)

April 19, 2024

Last Update Submitted That Met QC Criteria

April 18, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2022003398
  • 1R01HD092456-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified individual participant data that underlie the results reported for all primary and secondary outcome measures will be made available (text, tables, figures, and appendices).

IPD Sharing Time Frame

Beginning 6 months after study completion and ending 5 years following article publication.

IPD Sharing Access Criteria

Investigators whose proposed use of the data has been approved by an independent review committee identified for the purposes of reviewing proposals to gain access to these data. Requestors will need to provide a methodologically sound proposal, sign a data sharing agreement, and agree to the terms of data receipt.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Maternal Depression

Clinical Trials on Problem-solving education (PSE)

3
Subscribe